ClearPoint Neuro的激光疗法显示,在进一步验证之前,14名没有并发症的血浆瘤患者的存活率有所改善。 ClearPoint Neuro's laser therapy showed improved survival in 14 glioblastoma patients with no complications, pending further validation.

ClearPoint Neuro报告说,其 " 清点棱晶神经激光治疗系统 " 第一阶段-第二阶段研究在治疗有攻击性的脑肿瘤(如血浆瘤)方面取得了可喜成果,表明与14名没有与装置有关的并发症的病人相比,存活率有所提高,而以往的公开手术控制则有所改善。 ClearPoint Neuro reported promising results from a Phase I-II study of its ClearPoint Prism Neuro Laser Therapy System in treating aggressive brain tumors like glioblastoma, showing improved survival compared to historical open surgery controls in 14 patients with no device-related complications. 该研究在瑞典Skåne大学医院进行,由Peter Siesjö博士领导,表明该系统的安全性、可行性和潜在功效是最低限度的侵入性选择。 The study, conducted at Skåne University Hospital in Sweden and led by Dr. Peter Siesjö, demonstrated the system’s safety, feasibility, and potential efficacy as a minimally invasive option. 将在2025年10月举行的第75届神经外科医生年会上展示该技术,该技术使用精确成像制导激光烧蚀法。 The technology, which uses precise imaging-guided laser ablation, will be showcased at the 75th Annual Congress of Neurological Surgeons in October 2025. 公司的导航系统已获得FDA批准和CE标志, The company’s navigation system is FDA-cleared and CE-marked, with thousands of procedures performed globally. 虽然结果令人鼓舞,但该公司告诫说,未来的结果取决于监管、市场和筹资因素。 While the results are encouraging, the company cautioned that future outcomes depend on regulatory, market, and funding factors.